Cronos Current Deferred Revenue from 2010 to 2024

CRON Stock

CAD 2.72 0.07 2.51%

Cronos Current Deferred Revenue yearly trend continues to be very stable with very little volatility. Current Deferred Revenue is likely to grow to about 34 M this year. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals

Current Deferred Revenue

First Reported

2010-12-31

Previous Quarter

32.4 M

Current Value

34 M

Quarterly Volatility

14.8 M

Credit Downgrade

Yuan Drop

Covid

Check Cronos financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cronos' main balance sheet or income statement drivers, such as Interest Expense of 27.2 M, Selling General Administrative of 43.8 M or Total Revenue of 91.6 M, as well as many indicators such as Price To Sales Ratio of 8.66, Dividend Yield of 0.0 or PTB Ratio of 0.69. Cronos financial statements analysis is a perfect complement when working with Cronos Valuation or Volatility modules.

This module can also supplement various Cronos Technical models . Check out the analysis of Cronos Correlation against competitors.

When determining whether Cronos Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cronos' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cronos Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cronos Group Stock:

How To Invest In Cronos

Details

Is Cronos Stock a good investment?

Details

What is Cronos' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Cronos Correlation against competitors.

You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cronos Current Deferred Revenue from 2010 to 2024

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY